查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1750663

全球 COPD 和气喘治疗市场：市场规模、份额、趋势分析（按药品类别、设备/产品、技术/软体、适应症​​、分销管道和地区）、细分市场预测（2025-2030 年）

COPD And Asthma Therapeutics Market Size, Share & Trends Analysis Report By Drug Class, By Device/Product, By Technology/Software, By Indication, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

COPD 和气喘治疗的市场趋势：

预计 2024 年全球 COPD 和气喘治疗市场规模将达到 923 亿美元，2025 年至 2030 年的复合年增长率将达到 9.18%。

污染水平上升、烟草消费和人口老化加剧了慢性呼吸系统疾病的盛行率，大大增加了对支气管扩张剂、皮质类固醇和联合治疗的需求。

例如，根据全球气喘防治创议（GINA）预测，2022年全球气喘患者将超过2.62亿，世界卫生组织报告慢性阻塞性肺病（COPD）是全球第三大死因。此外，人口老化以及汽车和工业废气排放的增加是全球COPD和气喘治疗产业发展的主要驱动力。工业区附近空气品质恶化导致气喘盛行率上升。欧洲环境署表示，2021年的空气污染物水准大大超过了世界卫生组织（WHO）空气品质指南规定的水准。达到这些建议水准可防止欧盟成员国（EU-27）出现大量死亡，包括与接触细悬浮微粒（PM2.5）有关的253,000例死亡和与接触二氧化氮（NO2）有关的52,000例死亡。此外，减少短期接触臭氧（O3）可减少22,000例死亡。

慢性阻塞性肺病 (COPD) 和气喘治疗市场也受到药物输送设备技术进步的推动，例如蓝牙智慧吸入器和基于人工智慧的呼吸监测平台，这些设备提高了治疗依从性，并实现了远端系统管理。 Propeller Health 和 Teva 等公司已经推出了经 FDA核准的智慧吸入器，可以追踪药物使用并即时将数据传输给临床医生。

此外，行动医疗应用程式和远距呼吸解决方案日益普及，改善了医疗服务的可近性，尤其是在医疗资源匮乏的地区。线上药局和直销数位平台的扩张也简化了治疗途径，支持向居家疾病管理的转变。综合来看，这些药物类别、给药设备和数位工具的进步预计将使慢性阻塞性肺病和气喘市场在2030年之前保持持续成长。

医疗成本的上涨、发展中地区医疗服务可近性的改善以及政府旨在管理慢性呼吸系统疾病的支持政策进一步推动了市场潜力。印度和中国等国家全民健保体系的兴起，正在扩大基本吸入器和诊断设备的可近性。例如，中国的「健康中国2030」倡议着重于四大战略支柱：公平获取医疗服务及取得成果、医疗体系转型、技术与创新以及环境与气候永续性。公平是指导减少医疗体系障碍、改善全国健康状况的根本目标。

新冠疫情对慢性阻塞性肺病 (COPD) 和气喘治疗产业产生了积极影响。起初，由于医疗服务中断、肺功能检测减少以及诊断延误，治疗率和处方量有所下降。然而，随着疫情的进展，人们对呼吸系统健康的认识不断提高，以及慢性肺病患者出现严重后果的风险不断增加，维持治疗的依从性也随之提高。向居家医疗、远端医疗以及智慧吸入器和远端监控等数位健康工具的转变，为持续治疗和患者参与提供了支持。儘管市场面临短期挫折，但疫情最终强化了主动呼吸系统照护的重要性，并带来了长期成长机会。

目录

第一章 分析方法与范围

第二章执行摘要

第三章 市场驱动因素、趋势与范围

  • 市场联动展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
    • 产业机会分析
    • 产业挑战分析
    • 案例研究
  • 商业环境分析
    • 产业分析：波特五力分析
    • PESTEL分析
  • COVID-19影响分析

第四章 COPD 和气喘治疗市场：药物类别估计和趋势分析

  • 药品类别细分仪表板
  • 2024 年及 2030 年药物类别市场占有率变化分析
  • 2018-2030 年药品类别市场规模、预测及趋势分析
    • 支气管扩张剂
    • 皮质类固醇
    • 白三烯调节剂
    • 抗 IgE/抗 IL 单株抗体
    • 联合治疗
    • 其他的

第五章 COPD 和气喘治疗市场：按设备/产品的估计和趋势分析

  • 设备/产品仪表板
  • 按设备/产品分類的市场占有率和变化分析（2024 年和 2030 年）
  • 按设备/产品分類的市场规模、预测和趋势分析（2018-2030 年）
  • 吸入器
    • 吸入器市场（2018-2030）
  • 喷雾器
    • 雾化器市场（2018-2030）
  • 氧气疗法仪
    • 氧气疗法设备市场（2018-2030）

6. 慢性阻塞性肺病和气喘治疗市场：依技术/软体的估计和趋势分析

  • 技术/软体仪錶板
  • 按技术/软体分類的市场占有率和变化分析（2024 年和 2030 年）
  • 按技术/软体分類的市场规模、预测和趋势分析（2018-2030 年）
  • 蓝牙连接智慧吸入器
    • 蓝牙智慧吸入器市场（2018-2030）
  • 基于人工智慧的呼吸监测平台
    • 基于人工智慧的呼吸监测平台市场（2018-2030）
  • 症状追踪行动应用程式
    • 症状追踪行动应用市场（2018-2030）
  • 数位化合规与提醒系统
    • 数位合规与提醒系统市场（2018-2030）
  • 远端肺部疾病解决方案
    • 远距肺部疾病解决方案市场（2018-2030）

第七章 COPD 和气喘治疗市场：按适应症的估计和趋势分析

  • 指示仪表板
  • 市场占有率和趋势分析（按适应症划分）（2024 年和 2030 年）
  • 市场规模、预测与趋势分析（2018-2030 年）
  • 气喘
    • 气喘市场（2018-2030）
  • COPD
    • 慢性阻塞性肺病市场（2018-2030）

第 8 章：慢性阻塞性肺病和气喘治疗市场：按分销管道进行的估计和趋势分析

  • 按分销管道分類的仪表板
  • 按分销管道分類的市场占有率及变化分析（2024 年及 2030 年）
  • 按分销管道分類的市场规模、预测和趋势分析（2018-2030 年）
  • 医院药房
    • 医院药局市场（2018-2030）
  • 零售药局
    • 零售药局市场（2018-2030）
  • 网路药局
    • 药局市场（2018-2030）

第九章 COPD 和气喘治疗市场：按地区分類的估计和趋势分析

  • 区域市场仪表板
  • 区域市场：关键要点
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第十章 竞争格局

  • 参与企业概况
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • Teva Pharmaceutical Industries Ltd.
    • GSK plc
    • Merck &Co., Inc.
    • F. Hoffmann-La Roche Ltd
    • AstraZeneca
    • Boehringer Ingelheim International GmbH
    • Sanofi
    • Koninklijke Philips NV
    • BD
    • Covis Pharma
    • Findair Sp. z oo
    • Novartis AG
    • F. Hoffmann-La Roche Ltd
    • Cipla Ltd.
    • Chiesi Air
Product Code: GVR-4-68040-589-7

COPD & Asthma Therapeutics Market Trends:

The global COPD and asthma therapeutics market size was valued at USD 92.30 billion in 2024 and is expected to grow at a CAGR of 9.18% from 2025 to 2030. The increasing prevalence of chronic respiratory conditions, exacerbated by rising pollution levels, tobacco consumption, and aging populations, is significantly boosting demand for bronchodilators, corticosteroids, and combination therapies.

For instance, according to the Global Initiative for Asthma (GINA), asthma affected over 262 million people globally in 2022, while the WHO reported that COPD was the third leading cause of death worldwide. In addition, a growing aging population coupled with increasing automotive and industrial exhaust gases remains the key driver for the global COPD and asthma therapeutics industry. Degrading air quality near industrial areas has led to an increased incidence of asthma. According to the European Environment Agency, air pollutant levels in 2021 significantly exceeded the levels specified by the World Health Organization's (WHO) air quality guidelines. Achieving these recommended levels could have prevented a significant number of deaths across EU Member States (EU-27), including 253,000 deaths linked to exposure to fine particulate matter (PM2.5) and 52,000 deaths caused by nitrogen dioxide (NO2) exposure. In addition, reducing short-term exposure to ozone (O3) could have reduced 22,000 attributable deaths.

The COPD and asthma therapeutics market is also propelled by technological advancements in drug delivery devices, such as smart inhalers with Bluetooth connectivity and AI-based respiratory monitoring platforms, which enhance treatment adherence and enable remote patient management. Companies like Propeller Health and Teva have introduced FDA-approved smart inhalers that track medication usage and transmit data to clinicians in real time.

Moreover, the growing penetration of mobile health apps and telepulmonology solutions is improving access to care, especially in underserved areas. The expansion of online pharmacies and direct-to-consumer digital platforms is also streamlining therapy access, supporting the shift towards home-based disease management. Collectively, these advancements across therapeutic classes, delivery devices, and digital tools are expected to drive sustained growth in the COPD and asthma market through 2030.

Increasing healthcare expenditure, improved access to care in developing regions, and supportive government initiatives aimed at managing chronic respiratory conditions are further enhancing market potential. The rise of universal healthcare programs in countries such as India and China is expanding access to essential inhalers and diagnostics. For instance, China's Healthy China 2030 initiative focuses on four strategic pillars: equitable access and outcomes in health and healthcare, healthcare systems transformation, technology and innovation, and environmental and climate sustainability. Equity is the foundational goal, guiding efforts to reduce barriers in healthcare systems and improve health outcomes across the country.

The COVID-19 pandemic positively impacted the COPD and asthma therapeutics industry. Initially, disruptions in healthcare access, reduced pulmonary function testing, and delayed diagnoses led to a decline in treatment rates and prescription volumes. However, as the pandemic progressed, heightened awareness of respiratory health and the increased risk of severe COVID-19 outcomes in patients with chronic lung diseases drove greater adherence to maintenance therapies. The shift toward home-based care, telemedicine, and digital health tools, such as smart inhalers and remote monitoring, supported continued treatment and patient engagement. While the market faced short-term setbacks, the pandemic ultimately reinforced the importance of proactive respiratory care, leading to long-term growth opportunities.

Global COPD And Asthma Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global COPD and asthma therapeutics market report based on drug class, device/product, technology/software, indication, distribution channel, and region:

  • Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
  • Bronchodilators
  • Corticosteroids
  • Leukotriene Modifiers
  • Anti-IgE and Anti-IL Monoclonal Antibodies
  • Combination Therapy
  • Others
  • Device/Product Outlook (Revenue, USD Million, 2018 - 2030)
  • Inhalers
    • Dry Powder Inhalers (DPI)
    • Metered Dose Inhalers (MDI)
    • Soft Mist Inhalers (SMI)
  • Nebulizers
    • Jet
    • Mesh
    • Ultrasonic
  • Oxygen Therapy Devices
  • Technology/Software Outlook (Revenue, USD Million, 2018 - 2030)
  • Smart Inhalers with Bluetooth Connectivity
  • AI-based Respiratory Monitoring Platforms
  • Mobile Apps for Symptom Tracking
  • Digital Adherence and Reminder Systems
  • Telepulmonology Solutions
  • Indication Outlook (Revenue, USD Million, 2018 - 2030)
  • Asthma
  • COPD
  • Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Drug Stores
  • Regional Outlook (Revenue, USD Million, 2018 - 2030)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Device/Product
    • 1.2.3. Technology/Software
    • 1.2.4. Indication
    • 1.2.5. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Emergence of novel biologics
      • 3.2.1.2. Growing adoption of AI technologies in diagnostics, remote monitoring, and treatment optimization.
      • 3.2.1.3. Advancements in smart inhalers and digital health tools enhancing patient adherence and outcomes.
      • 3.2.1.4. Strong pipeline of innovative drugs and fixed-dose combination therapies.
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Regulatory hurdles and lengthy approval timelines for novel therapeutics.
      • 3.2.2.2. High cost of biologics and advanced therapies
    • 3.2.3. Industry Opportunity Analysis
    • 3.2.4. Industry Challenge Analysis
    • 3.2.5. Case Studies
  • 3.3. Business Environment Analysis
    • 3.3.1. Porter's Five Forces Analysis
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTLE Analysis
  • 3.4. COVID-19 Impact Analysis

Chapter 4. COPD and Asthma Therapeutics Market: Drug Class Estimates & Trend Analysis

  • 4.1. Drug Class Segment Dashboard
  • 4.2. Drug Class Market Share Movement Analysis, 2024 & 2030
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
    • 4.3.1. Bronchodilators
      • 4.3.1.1. Bronchodilators market, 2018 - 2030 (USD Million)
    • 4.3.2. Corticosteroids
      • 4.3.2.1. Corticosteroids market, 2018 - 2030 (USD Million)
    • 4.3.3. Leukotriene Modifiers
      • 4.3.3.1. Leukotriene Modifiers market, 2018 - 2030 (USD Million)
    • 4.3.4. Anti-IgE and Anti-IL Monoclonal Antibodies
      • 4.3.4.1. Anti-IgE and Anti-IL Monoclonal Antibodies market, 2018 - 2030 (USD Million)
    • 4.3.5. Combination Therapy
      • 4.3.5.1. Combination Therapy market, 2018 - 2030 (USD Million)
    • 4.3.6. Others
      • 4.3.6.1. Others market, 2018 - 2030 (USD Million)

Chapter 5. COPD and Asthma Therapeutics Market: Device/Product Estimates & Trend Analysis

  • 5.1. Device/Product Dashboard
  • 5.2. Device/Product Market Share Movement Analysis, 2024 & 2030
  • 5.3. Market Size & Forecasts and Trend Analysis, by Device/Product, 2018 to 2030 (USD Million)
  • 5.4. Inhalers
    • 5.4.1. Inhalers market, 2018 - 2030 (USD Million)
      • 5.4.1.1. Dry Powder Inhalers
      • 5.4.1.1.1.Dry Powder Inhalers market, 2018 - 2030 (USD Million)
      • 5.4.1.2. Metered Dose Inhalers
      • 5.4.1.2.1.Metered Dose Inhalers market, 2018 - 2030 (USD Million)
      • 5.4.1.3. Soft Mist Inhalers
      • 5.4.1.3.1.Soft Mist Inhalers market, 2018 - 2030 (USD Million)
  • 5.5. Nebulizers
    • 5.5.1. Nebulizers market, 2018 - 2030 (USD Million)
      • 5.5.1.1. Jet nebulizers
        • 5.5.1.1.1. Jet nebulizers market, 2018 - 2030 (USD Million)
      • 5.5.1.2. Mesh nebulizers
        • 5.5.1.2.1. Mesh nebulizers market, 2018 - 2030 (USD Million)
      • 5.5.1.3. Ultrasonic
        • 5.5.1.3.1. Ultrasonic Inhalers market, 2018 - 2030 (USD Million)
  • 5.6. Oxygen Therapy Devices
    • 5.6.1. Oxygen Therapy Devices market, 2018 - 2030 (USD Million)

Chapter 6. COPD and Asthma Therapeutics Market: Technology/Software Estimates & Trend Analysis

  • 6.1. Technology/Software Segment Dashboard
  • 6.2. Technology/Software Market Share Movement Analysis, 2024 & 2030
  • 6.3. Market Size & Forecasts and Trend Analysis, by Technology/Software, 2018 to 2030 (USD Million)
  • 6.4. Smart Inhalers with Bluetooth Connectivity
    • 6.4.1. Smart Inhalers with Bluetooth Connectivity market, 2018 - 2030 (USD Million)
  • 6.5. AI-based Respiratory Monitoring Platforms
    • 6.5.1. AI-based Respiratory Monitoring Platforms market, 2018 - 2030 (USD Million)
  • 6.6. Mobile Apps for Symptom Tracking
    • 6.6.1. Mobile Apps for Symptom Tracking market, 2018 - 2030 (USD Million)
  • 6.7. Digital Adherence and Reminder Systems
    • 6.7.1. Digital Adherence and Reminder Systems market, 2018 - 2030 (USD Million)
  • 6.8. Telepulmonology Solutions
    • 6.8.1. Telepulmonology Solutions market, 2018 - 2030 (USD Million)

Chapter 7. COPD and Asthma Therapeutics Market: Indication Estimates & Trend Analysis

  • 7.1. Indication Segment Dashboard
  • 7.2. Indication Market Share Movement Analysis, 2024 & 2030
  • 7.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
  • 7.4. Asthma
    • 7.4.1. Asthma market, 2018 - 2030 (USD Million)
  • 7.5. COPD
    • 7.5.1. COPD market, 2018 - 2030 (USD Million)

Chapter 8. COPD and Asthma Therapeutics Market: Distribution Channel Estimates & Trend Analysis

  • 8.1. Distribution Channel Segment Dashboard
  • 8.2. Distribution Channel Market Share Movement Analysis, 2024 & 2030
  • 8.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 8.4. Hospital Pharmacies
    • 8.4.1. Hospital Pharmacies market, 2018 - 2030 (USD Million)
  • 8.5. Retail Pharmacies
    • 8.5.1. Retail Pharmacies market, 2018 - 2030 (USD Million)
  • 8.6. Online Pharmacies
    • 8.6.1. Drug Stores market, 2018 - 2030 (USD Million)

Chapter 9. COPD and Asthma Therapeutics Market: Regional Estimates & Trend Analysis

  • 9.1. Regional Market Dashboard
  • 9.2. Regional Market: Key Takeaways
  • 9.3. North America
    • 9.3.1. North America COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.3.2. U.S.
      • 9.3.2.1. Key country dynamic
      • 9.3.2.2. Regulatory framework
      • 9.3.2.3. Competitive insights
      • 9.3.2.4. U.S. COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.3.3. Canada
      • 9.3.3.1. Key country dynamic
      • 9.3.3.2. Regulatory framework
      • 9.3.3.3. Competitive insights
      • 9.3.3.4. Canada COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.3.4. Mexico
      • 9.3.4.1. Key country dynamic
      • 9.3.4.2. Regulatory framework
      • 9.3.4.3. Competitive insights
      • 9.3.4.4. Mexico COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4. Europe
    • 9.4.1. Europe COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.4.2. Germany
      • 9.4.2.1. Key country dynamic
      • 9.4.2.2. Regulatory framework
      • 9.4.2.3. Competitive insights
      • 9.4.2.4. Germany COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.4.3. UK
      • 9.4.3.1. Key country dynamic
      • 9.4.3.2. Regulatory framework
      • 9.4.3.3. Competitive insights
      • 9.4.3.4. UK COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.4.4. France
      • 9.4.4.1. Key country dynamic
      • 9.4.4.2. Regulatory framework
      • 9.4.4.3. Competitive insights
      • 9.4.4.4. France COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.4.5. Italy
      • 9.4.5.1. Key country dynamic
      • 9.4.5.2. Regulatory framework
      • 9.4.5.3. Competitive insights
      • 9.4.5.4. Italy COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.4.6. Spain
      • 9.4.6.1. Key country dynamic
      • 9.4.6.2. Regulatory framework
      • 9.4.6.3. Competitive insights
      • 9.4.6.4. Spain COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.4.7. Denmark
      • 9.4.7.1. Key country dynamic
      • 9.4.7.2. Regulatory framework
      • 9.4.7.3. Competitive insights
      • 9.4.7.4. Denmark COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.4.8. Sweden
      • 9.4.8.1. Key country dynamic
      • 9.4.8.2. Regulatory framework
      • 9.4.8.3. Competitive insights
      • 9.4.8.4. Sweden COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.4.9. Norway
      • 9.4.9.1. Key country dynamic
      • 9.4.9.2. Regulatory framework
      • 9.4.9.3. Competitive insights
      • 9.4.9.4. Norway COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.5. Asia Pacific
    • 9.5.1. Asia Pacific COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.5.2. Japan
      • 9.5.2.1. Key country dynamic
      • 9.5.2.2. Regulatory framework
      • 9.5.2.3. Competitive insights
      • 9.5.2.4. Japan COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.5.3. China
      • 9.5.3.1. Key country dynamic
      • 9.5.3.2. Regulatory framework
      • 9.5.3.3. Competitive insights
      • 9.5.3.4. China COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.5.4. India
      • 9.5.4.1. Key country dynamic
      • 9.5.4.2. Regulatory framework
      • 9.5.4.3. Competitive insights
      • 9.5.4.4. India COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.5.5. South Korea
      • 9.5.5.1. Key country dynamic
      • 9.5.5.2. Regulatory framework
      • 9.5.5.3. Competitive insights
      • 9.5.5.4. South Korea COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.5.6. Australia
      • 9.5.6.1. Key country dynamic
      • 9.5.6.2. Regulatory framework
      • 9.5.6.3. Competitive insights
      • 9.5.6.4. Australia COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.5.7. Thailand
      • 9.5.7.1. Key country dynamic
      • 9.5.7.2. Regulatory framework
      • 9.5.7.3. Competitive insights
      • 9.5.7.4. Thailand COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.6. Latin America
    • 9.6.1. Latin America COPD and Asthma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.2. Brazil
      • 9.6.2.1. Key country dynamic
      • 9.6.2.2. Regulatory framework
      • 9.6.2.3. Competitive insights
      • 9.6.2.4. Brazil COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.6.3. Argentina
      • 9.6.3.1. Key country dynamic
      • 9.6.3.2. Regulatory framework
      • 9.6.3.3. Competitive insights
      • 9.6.3.4. Argentina COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.7. MEA
    • 9.7.1. MEA COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.7.2. South Africa
      • 9.7.2.1. Key country dynamic
      • 9.7.2.2. Regulatory framework
      • 9.7.2.3. Competitive insights
      • 9.7.2.4. South Africa COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.7.3. Saudi Arabia
      • 9.7.3.1. Key country dynamic
      • 9.7.3.2. Regulatory framework
      • 9.7.3.3. Competitive insights
      • 9.7.3.4. Saudi Arabia COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.7.4. UAE
      • 9.7.4.1. Key country dynamic
      • 9.7.4.2. Regulatory framework
      • 9.7.4.3. Competitive insights
      • 9.7.4.4. UAE COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.7.5. Kuwait
      • 9.7.5.1. Key country dynamic
      • 9.7.5.2. Regulatory framework
      • 9.7.5.3. Competitive insights
      • 9.7.5.4. Kuwait COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Participant Overview
  • 10.2. Company Market Position Analysis
  • 10.3. Company Categorization
  • 10.4. Strategy Mapping
  • 10.5. Company Profiles/Listing
    • 10.5.1. Teva Pharmaceutical Industries Ltd.
      • 10.5.1.1. Overview
      • 10.5.1.2. Financial performance
      • 10.5.1.3. Product benchmarking
      • 10.5.1.4. Strategic initiatives
    • 10.5.2. GSK plc
      • 10.5.2.1. Overview
      • 10.5.2.2. Financial performance
      • 10.5.2.3. Product benchmarking
      • 10.5.2.4. Strategic initiatives
    • 10.5.3. Merck & Co., Inc.
      • 10.5.3.1. Overview
      • 10.5.3.2. Financial performance
      • 10.5.3.3. Product benchmarking
      • 10.5.3.4. Strategic initiatives
    • 10.5.4. F. Hoffmann-La Roche Ltd
      • 10.5.4.1. Overview
      • 10.5.4.2. Financial performance
      • 10.5.4.3. Product benchmarking
      • 10.5.4.4. Strategic initiatives
    • 10.5.5. AstraZeneca
      • 10.5.5.1. Overview
      • 10.5.5.2. Financial performance
      • 10.5.5.3. Product benchmarking
      • 10.5.5.4. Strategic initiatives
    • 10.5.6. Boehringer Ingelheim International GmbH
      • 10.5.6.1. Overview
      • 10.5.6.2. Financial performance
      • 10.5.6.3. Product benchmarking
      • 10.5.6.4. Strategic initiatives
    • 10.5.7. Sanofi
      • 10.5.7.1. Overview
      • 10.5.7.2. Financial performance
      • 10.5.7.3. Product benchmarking
      • 10.5.7.4. Strategic initiatives
    • 10.5.8. Koninklijke Philips N.V.
      • 10.5.8.1. Overview
      • 10.5.8.2. Financial performance
      • 10.5.8.3. Product benchmarking
      • 10.5.8.4. Strategic initiatives
    • 10.5.9. BD
      • 10.5.9.1. Overview
      • 10.5.9.2. Financial performance
      • 10.5.9.3. Product benchmarking
    • 10.5.10. Covis Pharma
      • 10.5.10.1. Overview
      • 10.5.10.2. Financial performance
      • 10.5.10.3. Product benchmarking
    • 10.5.11. Findair Sp. z o. o.
      • 10.5.11.1. Overview
      • 10.5.11.2. Financial performance
      • 10.5.11.3. Product benchmarking
    • 10.5.12. Novartis AG
      • 10.5.12.1. Overview
      • 10.5.12.2. Financial performance
      • 10.5.12.3. Product benchmarking
    • 10.5.13. F. Hoffmann-La Roche Ltd
      • 10.5.13.1. Overview
      • 10.5.13.2. Financial performance
      • 10.5.13.3. Product benchmarking
    • 10.5.14. Cipla Ltd.
      • 10.5.14.1. Overview
      • 10.5.14.2. Financial performance
      • 10.5.14.3. Product benchmarking
    • 10.5.15. Chiesi Air
      • 10.5.15.1. Overview
      • 10.5.15.2. Financial performance
      • 10.5.15.3. Product benchmarking

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. North America COPD and asthma therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 4. North America COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 5. North America COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 6. North America COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 7. North America COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 8. North America COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 9. U.S. COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 10. U.S. COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 11. U.S. COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 12. U.S. COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 13. U.S. COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 14. Canada COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 15. Canada COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 16. Canada COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 17. Canada COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 18. Canada COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 19. Mexico COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 20. Mexico COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 21. Mexico COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 22. Mexico COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 23. Mexico COPD and asthma therapeutics market, by distribution channel scope, 2018-
  • Table 24. Europe COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 25. Europe COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 26. Europe COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 27. Europe COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 28. Europe COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 29. UK COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 30. UK COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 31. UK COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 32. UK COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 33. UK COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 34. Germany COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 35. Germany COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 36. Germany COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 37. Germany COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 38. Germany COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 39. France COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 40. France COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 41. France COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 42. France COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 43. France COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 44. Italy COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 45. Italy COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 46. Italy COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 47. Italy COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 48. Italy COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 49. Spain COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 50. Spain COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 51. Spain COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 52. Spain COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 53. Spain COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 54. Norway COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 55. Norway COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 56. Norway COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 57. Norway COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 58. Norway COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 59. Sweden COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 60. Sweden COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 61. Sweden COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 62. Sweden COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 63. Sweden COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 64. Denmark COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 65. Denmark COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 66. Denmark COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 67. Denmark COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 68. Denmark COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 69. Asia Pacific COPD and asthma therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 70. Asia Pacific COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 71. Asia Pacific COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 72. Asia Pacific COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 73. Asia Pacific COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 74. Asia Pacific COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 75. Japan COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 76. Japan COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 77. Japan COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 78. Japan COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 79. Japan COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 80. China COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 81. China COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 82. China COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 83. China COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 84. China COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 85. India COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 86. India COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 87. India COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 88. India COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 89. India COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 90. Australia COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 91. Australia COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 92. Australia COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 93. Australia COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 94. Australia COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 95. South Korea COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 96. South Korea COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 97. South Korea COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 98. South Korea COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 99. South Korea COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 100. Thailand COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 101. Thailand COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 102. Thailand COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 103. Thailand COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 104. Thailand COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 105. Latin America COPD and asthma therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 106. Latin America COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 107. Latin America COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 108. Latin America COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 109. Latin America COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 110. Latin America COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 111. Brazil COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 112. Brazil COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 113. Brazil COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 114. Brazil COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 115. Brazil COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 116. Argentina COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 117. Argentina COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 118. Argentina COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 119. Argentina COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 120. Argentina COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 121. Middle East & Africa COPD and asthma therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 122. Middle East & Africa COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 123. Middle East & Africa COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 124. Middle East & Africa COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 125. Middle East & Africa COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 126. Middle East & Africa COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 127. South Africa COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 128. South Africa COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 129. South Africa COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 130. South Africa COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 131. South Africa COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 132. Saudi Arabia COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 133. Saudi Arabia COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 134. Saudi Arabia COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 135. Saudi Arabia COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 136. Saudi Arabia COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 137. UAE COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 138. UAE COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 139. UAE COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 140. UAE COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 141. UAE COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 142. Kuwait COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 143. Kuwait COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 144. Kuwait COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 145. Kuwait COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 146. Kuwait COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 COPD and asthma therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market formulation & validation
  • Fig. 6 Market research approaches
  • Fig. 7 Value-chain-based sizing & forecasting
  • Fig. 8 QFD modelling for market share assessment
  • Fig. 9 Commodity flow analysis
  • Fig. 10 Market snapshot
  • Fig. 11 Market segmentation (USD Million)
  • Fig. 12 Competitive landscape
  • Fig. 13 Parent market outlook (In USD Billion)
  • Fig. 14 Related/ancillary market outlook (In USD Billion)
  • Fig. 15 COPD and asthma therapeutics market dynamics
  • Fig. 16 COPD and asthma therapeutics market: Porter's five forces analysis
  • Fig. 17 COPD and asthma therapeutics market: PESTLE analysis
  • Fig. 18 COPD and asthma therapeutics market: Drug class segment dashboard
  • Fig. 19 COPD and asthma therapeutics market: Drug class market share analysis, 2024 & 2030
  • Fig. 20 Bronchodilators market, 2018 - 2030 (USD Million)
  • Fig. 21 Corticosteroids market, 2018 - 2030 (USD Million)
  • Fig. 22 Leukotriene Modifiers market, 2018 - 2030 (USD Million)
  • Fig. 23 Anti-IgE and Anti-IL Monoclonal Antibodies market, 2018 - 2030 (USD Million)
  • Fig. 24 Combination Therapy market, 2018 - 2030 (USD Million)
  • Fig. 25 Others market, 2018 - 2030 (USD Million)
  • Fig. 26 COPD and asthma therapeutics market: Device/Product segment dashboard
  • Fig. 27 COPD and asthma therapeutics market: Device/Product market share analysis, 2024 & 2030
  • Fig. 28 Inhalers market, 2018 - 2030 (USD Million)
  • Fig. 29 Nebulizers market, 2018 - 2030 (USD Million)
  • Fig. 30 Oxygen Therapy Devices market, 2018 - 2030 (USD Million)
  • Fig. 31 COPD and asthma therapeutics market: Technology/Software segment dashboard
  • Fig. 32 COPD and asthma therapeutics market: Technology/Software market share analysis, 2024 & 2030
  • Fig. 33 Smart Inhalers with Bluetooth Connectivity market, 2018 - 2030 (USD Million)
  • Fig. 34 AI-based Respiratory Monitoring Platforms market, 2018 - 2030 (USD Million)
  • Fig. 35 Mobile Apps for Symptom Tracking market, 2018 - 2030 (USD Million)
  • Fig. 36 Digital Adherence and Reminder Systems market, 2018 - 2030 (USD Million)
  • Fig. 37 Telepulmonology Solutions and Reminder Systems market, 2018 - 2030 (USD Million)
  • Fig. 38 COPD and asthma therapeutics market: Indication market share analysis, 2024 & 2030
  • Fig. 39 Asthma market, 2018 - 2030 (USD Million)
  • Fig. 40 COPD market, 2018 - 2030 (USD Million
  • Fig. 41 COPD and asthma therapeutics market revenue, by region
  • Fig. 42 Regional marketplace: Key takeaways
  • Fig. 43 North America COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 US COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 46 Key country dynamics
  • Fig. 47 Canada COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 Mexico COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 50 Europe COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 UK COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 Germany COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 France COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Italy COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Spain COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Norway COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 Sweden COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 Denmark COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 67 Asia Pacific COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 Japan COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 China COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 India COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Australia COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 South Korea COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 Thailand COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 80 Latin America COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 81 Key country dynamics
  • Fig. 82 Brazil COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 83 Key country dynamics
  • Fig. 84 Argentina COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 85 MEA COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 South Africa COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 88 Key country dynamics
  • Fig. 89 Saudi Arabia COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 90 Key country dynamics
  • Fig. 91 UAE COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 92 Key country dynamics
  • Fig. 93 Kuwait healthcare information system market, 2018 - 2030 (USD Million)
  • Fig. 94 Company categorization
  • Fig. 95 Company market position analysis
  • Fig. 96 Strategic framework